Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:17 pm EDT
Share
Relay Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 25.2 million compared to USD 0.344 million a year ago. Net loss was USD 65.73 million compared to USD 84.17 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.76 a year ago.
For the nine months, revenue was USD 25.55 million compared to USD 1.13 million a year ago. Net loss was USD 258.48 million compared to USD 223.01 million a year ago. Basic loss per share from continuing operations was USD 2.12 compared to USD 2.04 a year ago.
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Companyâs Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Companyâs lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
RELAY THERAPEUTICS, INC. 
